Decera Clinical Education Oncology Podcast

Decera Clinical Education
  • 5.0（2）
  • コース
  • アップデート：毎週

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

  1. Beyond Chemotherapy in ALL: Emerging Bispecific Antibodies, CAR T-cell Therapies, and Evolving Treatment Strategies

    2月27日

    Beyond Chemotherapy in ALL: Emerging Bispecific Antibodies, CAR T-cell Therapies, and Evolving Treatment Strategies

    In this episode, Dr Ibrahim Aldoss and Dr Bijal Shah discuss how immunotherapy has transformed the treatment landscape of acute lymphoblastic leukemia (ALL), particularly in relapsed/refractory B-cell ALL, including: CD19-directed CAR T-cell therapies Next-generation CD19 bispecific antibodies The evolving role of allogeneic transplant Presenters: Ibrahim Aldoss, MD Associate Professor Division of Leukemia Department of Hematology/HCT City of Hope National Medical Center Duarte, California Bijal Shah, MD, MS Senior Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, Florida Link to full program: https://bit.ly/4cRjiUi Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    39分
  2. Experts Discuss Novel RAS-Targeted Therapy for Pancreatic Cancer

    2月23日

    Experts Discuss Novel RAS-Targeted Therapy for Pancreatic Cancer

    In this podcast episode, Nilofer Azad, MD, FASCO, and Zev A. Wainberg, MD, discuss novel RAS-targeted therapies for pancreatic cancer, including the following: Optimal KRAS mutation testing Emerging multiselective RAS inhibitors Combination strategies Presenters:  Nilofer Azad, MD, FASCO Professor of Oncology Associate Director of Clinical Research Sidney Kimmel Cancer Center at Johns Hopkins University Co-Leader, Developmental Therapeutics Clinical Trials Group Baltimore, Maryland Zev A. Wainberg, MD Professor of Medicine and Surgery Co-Director, GI Oncology Program UCLA School of Medicine Los Angeles, California Content based on an online CME program supported by an educational grant from Revolution Medicines, Inc. Link to full program: https://bit.ly/4avdRZK Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    22分
  3. Advanced Practice Professionals Discuss Biomarker Testing in Patients With Solid Tumors: Lung Cancer

    2月20日

    Advanced Practice Professionals Discuss Biomarker Testing in Patients With Solid Tumors: Lung Cancer

    Advanced practice providers discuss biomarker testing in patients with lung cancer. Listen in to learn from Beth Sandy, MSN, CRNP,FAPO, and Denise Rouse, MS, PA-C, about key biomarker testing in patients with lung cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker testing in patients with lung cancer. Presenters: Beth Sandy, MSN, CRNP, FAPO  Thoracic Oncology Nurse Practitioner Abramson Cancer Center University of Pennsylvania Philadelphia, Pennsylvania Denise Rouse, MS, PA-C  Physician Assistant Thoracic Medical Oncology Department of Medicine, Section of Hematology/Oncology The University of Chicago Medicine & Biological Sciences Chicago, Illinois Link to full program: https://bit.ly/4rt1OCl Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    48分

  4. 1月30日

    Individualized Hemophilia Care With Hemostatic Rebalancing Therapies

    In this podcast episode, experts Angela Weyand and Guy Young discuss their experience using hemostatic rebalancing agents for prophylaxis in patients diagnosed with hemophilia. Three rebalancing agents have now been approved, including concizumab, fitusiran, and marstacimab. These new rebalancing agents target the body's natural anticoagulants and provide individualized, convenient options for patients older than 12 years of age.This podcast explores similarities and differences between the rebalancing agents, such as dosing, necessary lab testing, and safety profiles, that are important to discuss with patients and their caregivers. Presenters: Angela Weyand, MD Associate Professor, Pediatric Hematology Oncology Co-Director, Combined Hematology/Gynecology Program Pediatric Medical Director, Hemophilia Treatment Center University of Michigan Medical School Ann Arbor, Michigan Guy Young, MD Director, Hemostasis and Thrombosis Center Director, Clinical Coagulation Laboratory Cancer and Blood Disease Institute Children's Hospital Los Angeles Professor of Pediatrics Division of Hematology/Oncology Department of Pediatrics University of Southern California Keck School of Medicine Los Angeles, California Get access to all of our new podcasts by subscribing to the CCO Neuroscience Podcast on Apple Podcasts, YouTube Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    29分
  5. Experts Offer Guidance on Shared Decision-making in the Management of Patients With PV/ET

    1月21日

    Experts Offer Guidance on Shared Decision-making in the Management of Patients With PV/ET

    In this episode, hear Joan How, MD and Pankit Vachhani, MD share their insights on the importance of shared decision-making (SDM) for patients with polycythemia vera (PV) or essential thrombocythemia (ET) including:  Personal insights and examples of the process of SDM with patients with PV or ETHow nuances of managing PV/ET influence SDMIndividualizing the process of SDMBarriers to effective SDMEducational resources for patients with PV, ET, or MPNsWorking with a team to incorporate SDM into clinical practiceProgram faculty: Joan How, MD Scientific and Medical Consultant Clinical Chief of Hematology Brigham and Women's Faulkner Hospital Associate Physician Brigham and Women's Hospital Assistant Professor in Medicine Harvard Medical School Boston, Massachusetts Pankit Vachhani, MD Associate Professor of Medicine Division of Hematology and Oncology University of Alabama at Birmingham O’Neal Comprehensive Cancer Center at the UAB Birmingham, Alabama Link to obtain CME/CE credit: https://bit.ly/3ZtxWJm Link to program page:  https://bit.ly/3YQKlHb Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    31分
  6. Experts Discuss CELMoD Agents for Treating Multiple Myeloma

    2025/12/30

    Experts Discuss CELMoD Agents for Treating Multiple Myeloma

    In this podcast episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Niels van de Donk, MD, PhD, address key questions on CELMoD agent therapy for multiple myeloma, including: Combination strategiesAdverse event managementWhere CELMoD agents may best fit within current and future treatment strategies Presenters:  Jesus Berdeja, MD Director of Multiple Myeloma Research Greco-Hainsworth Centers for Research Tennessee Oncology Nashville, Tennessee Amrita Krishnan, MD, FACP Director, Judy and Bernard Center for Myeloma, City of Hope Nason Hollingsworth Family Chair Myeloma Executive Director, Hematology, City of Hope Orange County Professor Hematology/HCT Irvine, California  Niels van de Donk, MD, PhD Professor of Hematology Department of Hematology Amsterdam UMC, Location VUmc Amsterdam, Netherlands Content based on an online CME program supported by an educational grant from Bristol Myers Squibb. Link to full program: https://bit.ly/4qvRwQM Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    18分
  7. PulseCast: Highlights in MDS/MPNs From the 2025 ASH Annual Meeting

    2025/12/30

    PulseCast: Highlights in MDS/MPNs From the 2025 ASH Annual Meeting

    In this podcast episode, Rami Komrokji, MD, reviews data from select presentations in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) presented at the ASH 2025 Annual Meeting and shares expert perspectives on the clinical implications of these findings, including: Abstract 910: MANIFEST-2 96-Wk Update: Ruxolitinib + Pelabresib or Placebo in Patients With JAK Inhibitor–Naive MFAbstract 1024: Phase I Trial of INCA033989, a First-in-Class Antibody Targeting Mutant Calreticulin: Safety and Efficacy in Essential ThrombocythemiaAbstract 484: Preliminary Results From 2 Phase I Trials Exploring the Mutant Calreticulin-Specific mAb INCA033989 ± Ruxolitinib in Patients With MFAbstract 235: VERONA: Subgroup Analyses of Venetoclax or Placebo Combined With Azacitidine in Treatment-Naive Higher-Risk MDSAbstract 490: IMerge Post Hoc Analysis: Treatment-Emergent Cytopenias and Response With Imetelstat in Patients With Lower-Risk MDSAbstract 487: Randomized Phase II Trial of Reduced Treatment Durations of Hypomethylating Agents for Lower-Risk MDSPresenter:  Rami Komrokji, MD Senior Member, Vice Chair Section Head – Leukemia and MDS Department of Malignant Hematology H. Lee Moffitt Cancer Center Professor of Oncologic Sciences University of South Florida Tampa, Florida Content based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation. Link to full program:  https://bit.ly/48Ye45N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    15分
  8. Expert Highlights From the 2025 World Conference on Lung Cancer

    2025/12/24

    Expert Highlights From the 2025 World Conference on Lung Cancer

    In this episode, Dr John Heymach and Dr Solange Peters discuss key data presented at the IASLC World Conference on Lung Cancer including first-line maintenance in ES-SCLC (IMforte and DeLLphi-303 trials) and targeted treatment for NSCLC (FLAURA2, Beamion LUNG-1, and ARROS-1 trials). Presenters: John Heymach, MD, PhD Chair and Professor Department of Thoracic/Head and Neck Medical Oncology Ruth Legett Jones Distinguished Chair MD Anderson Cancer Center Houston, Texas Solange Peters, MD, PhD  Professor and Director of Medical Oncology Department of Oncology University Hospital of Lausanne Lausanne, Switzerland Content based on an online CME program supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc. Link to full program:  https://bit.ly/3L1eksI Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    25分
すべて見る（228）

評価とレビュー

5
5段階評価中
2件の評価

番組について

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

情報

  • クリエイター
    Decera Clinical Education
  • 配信期間
    20年 - 26年
  • エピソード
    228
  • 制限指定
    不適切な内容を含まない
  • Copyright
    © 2020 Decera Clinical Education Oncology Podcast
  • 番組のWebサイト
    Decera Clinical Education Oncology Podcast

その他のおすすめ